Am­gen, As­traZeneca bol­ster their case for break­through asth­ma pro­gram as FDA con­sid­ers tak­ing up a re­view

Just a few days af­ter sub­mit­ting a BLA for their high­ly-tout­ed asth­ma pro­gram, Am­gen and As­traZeneca re­leased new da­ta they hope will con­tin­ue to strength­en …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER